AGENCIES: Britain’s AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects, giving the world another important tool to halt the COVID-19 pandemic. The combined analysis from both dosing regimens resulted in an average efficacy of 70%.
The vaccine developed by Oxford University was 90% effective in preventing COVID-19 when it was administered as a half dose followed by a full dose at least one month apart, according to data from the late-stage trials in Britain and Brazil.
“We are excited to see 90% efficacy from the half dose-full dose regimen,” an Astra spokesman said. “We see a lot of merit in this regimen and we will now start discussions with regulators into incorporating this dose combination for further clinical investigation.”
The Serum Institute of India, the world’s largest manufacturer of vaccines by volume, has partnered with AstraZeneca, the Gates Foundation and the Gavi vaccine alliance to produce more than a billion doses of a COVID-19 vaccine for global supply.
I am delighted to hear that, Covishield, a low-cost, logistically manageable & soon to be widely available, #COVID19 vaccine, will offer protection up to 90% in one type of dosage regime and 62% in the other dosage regime. Further details on this, will be provided this evening. https://t.co/KCr3GmROiW
— Adar Poonawalla (@adarpoonawalla) November 23, 2020